← Eichor
Condition: Prostate Specific Antigen Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Prostate Specific Antigen

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique
Phase 2 · 1 location(s) · Emory University · NCT06865768High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy
Phase N/A · 1 location(s) · Clinica Universidad de Navarra, Universidad de Navarra · NCT06982469Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
Phase N/A · 2 location(s) · Massachusetts General Hospital · NCT06862856A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Phase 1 · 6 location(s) · Janssen Research & Development, LLC · NCT07082920Androgen-responsive POSLUMA-guided Intra-prostatic Boost
Phase 2 · 4 location(s) · Martin T. King, MD, PhD · NCT07393867Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance
NA · 4 location(s) · Weill Medical College of Cornell University · NCT05948657A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prost
Phase 1/Phase 2 · 2 location(s) · Yunhe Pharmaceutical (Tianjin) Co., Ltd · NCT06970119Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE
Phase N/A · 1 location(s) · Azienda Ospedaliero-Universitaria Careggi · NCT05022914An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Phase 3 · 147 location(s) · Novartis Pharmaceuticals · NCT05939414Pathological Positivity Rate in Prostate Cancer Patients with PI-RADS 4 and First Negative Biopsy
Phase N/A · 1 location(s) · Anhui Provincial Hospital · NCT06677775A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Phase 1/Phase 2 · 2 location(s) · C Ray Therapeutics · NCT07567521Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Phase 1/Phase 2 · 35 location(s) · AstraZeneca · NCT07590934Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
Phase N/A · 1 location(s) · Lithuanian University of Health Sciences · NCT07516886PSMA-specific CAR-T Cell Therapy
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04429451Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer
NA · 15 location(s) · Imperial College London · NCT05574647Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)
Phase 2 · 12 location(s) · Fundacion Oncosur · NCT06582628Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
Phase 1 · 1 location(s) · The Affiliated Hospital of Xuzhou Medical University · NCT05354375Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study
Phase N/A · 1 location(s) · Queen Mary University of London · NCT06987045Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-
Phase 2 · 2 location(s) · University of Washington · NCT04175431PSMA PET Combined With MRI for the Detection of PCa
Phase 3 · 18 location(s) · Telix Pharmaceuticals (Innovations) Pty Limited · NCT07052214Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)
Phase N/A · 1 location(s) · Northwestern University · NCT06804785Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Phase 2 · 1 location(s) · University of Wisconsin, Madison · NCT04573231European Registry of Next Generation Imaging in Advanced Prostate Cancer
Phase N/A · 24 location(s) · Fundacio Puigvert · NCT06866782Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
Phase 1/Phase 2 · 1 location(s) · Milton S. Hershey Medical Center · NCT06600698Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
Phase N/A · 2 location(s) · Tianjin Medical University · NCT06690970Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient
Phase N/A · 1 location(s) · Assiut University · NCT06209853Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.
NA · 3 location(s) · Lund University Hospital · NCT04858880Determination of Prostate-specific Antigen in Capillary Blood (PSA-Cap)
Phase N/A · 1 location(s) · Heinrich-Heine University, Duesseldorf · NCT06626386Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
NA · 1 location(s) · University Health Network, Toronto · NCT06335914
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.